US2003031666A1PendingUtilityA1

Antibodies that bind IL-13 mutants

51
Priority: Apr 3, 1998Filed: Jan 17, 2002Published: Feb 13, 2003
Est. expiryApr 3, 2018(expired)· nominal 20-yr term from priority
Inventors:Waldemar DebinskiJeffrey P. Thompson
A61K 38/00C07K 14/5437C07K 2319/00C07K 14/21
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention provides antibodies that bind mutant human interleukin 13 molecules showing varying specificity for the restricted (IL4 independent) IL13 receptor. The mutant hIL13 molecules include those made by substituting the amino acid residues that occur in the alpha-helix regions of native hIL13 with various other amino acid residues. Some of the mutants retain the ability to bind and cause signaling through IL13 receptors, while other mutants do not.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An antibody that specifically binds a mutant hIL13 molecule but not a native hIL13 molecule.  
     
     
         2 . The antibody of  claim 1 , wherein the antibody is a monoclonal antibody.  
     
     
         3 . The antibody of  claim 1 , wherein the antibody is a polyclonal antibody.  
     
     
         4 . The antibody of  claim 1 , wherein the mutant hIL13 is a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID Nos: 2-23.  
     
     
         5 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2.  
     
     
         6 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 3.  
     
     
         7 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4.  
     
     
         8 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 5.  
     
     
         9 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 6.  
     
     
         10 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 7.  
     
     
         11 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 8.  
     
     
         12 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 9.  
     
     
         13 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 10.  
     
     
         14 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 11.  
     
     
         15 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 12.  
     
     
         16 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 13.  
     
     
         17 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 14.  
     
     
         18 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 15.  
     
     
         19 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 16.  
     
     
         20 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 17.  
     
     
         21 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 18.  
     
     
         22 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 19.  
     
     
         23 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 20.  
     
     
         24 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 21.  
     
     
         25 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 22.  
     
     
         26 . The antibody of  claim 4 , wherein the mutant hIL13 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 23.

Join the waitlist — get patent alerts

Track US2003031666A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.